NCT01643083

Rifaximin for Functional Dyspepsia

Use of Rifaximin in Patients With Functional Dyspepsia: A Randomized Controlled Trial

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 95 (actual)
• Sponsor: The University of Hong Kong · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Functional dyspepsia is a very common medical condition, which occurs in up to 30% of people in the community. However, results of current pharmacological treatment on functional dyspepsia are unsatisfactory. Rifaximin is a minimally absorbed antibiotic that has been used in treatment of non-constipated irritable bowel syndrome (IBS). In particular, bloating and abdominal pain was improved by rifaximin treatment in this group of IBS patients. Whilst there is considerable overlap in symptoms of functional dyspepsia and IBS, the investigators test whether rifaximin is also effective in curing post-prandial distress symptoms related to dyspepsia.

Detailed description

The aim of this study is to test the effects of rifaximin, a minimally absorbed antibiotics, on symptoms of patients with functional dyspepsia.

Conditions

• Functional Dyspepsia

Interventions

Type	Name	Description
DRUG	Rifaximin	Rifaximin 400mg tid for 2 wk
DRUG	Placebo	Placebo for 2 week

Timeline

• Start date: 2013-01-01
• Primary completion: 2015-05-01
• Completion: 2015-05-01
• First posted: 2012-07-17
• Last updated: 2015-12-02

Locations

1 site across 1 country: China